Cookie Settings
 
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Welcome to Nexplace: the home of
NEXPLANON® (etonogestrel 68 mg implant)

NEXPLANON® is indicated for contraception. Safety and efficacy have been established in women between 18 and 40 years of age.1

Login/Register

To view the content on this page

Your questions answered

Do you still have unanswered questions about NEXPLANON® or other LARCs? Explore the list below for the answers to some of the questions that you or your patients may have.

My patient has been on injectable contraception for longer than 2 years, what should I do?

My patient has missed one or more contraception-related appointments in the last year, what should I do?

When should NEXPLANON® be inserted and does it start working immediately?

Is NEXPLANON® effective in heavier women?

What bleeding patterns can women expect while on NEXPLANON®?

My patient’s implant is no longer palpable. What should I do?

I would like to gain a qualification in fitting and removing implants. How do I do this?

Are there any side effects with NEXPLANON®?

Questions your patients may have

The answers to these questions are aimed at patients. They do not provide guidance for the use of NEXPLANON® by HCPs and should not be used as such. Please refer to the Summary of Product Characteristics for full details on the use of NEXPLANON®.

Can I switch to the implant from another method of contraception?

How long does it take to insert the implant?

Will having the implant inserted hurt?

How is the implant removed?

How long does it take to remove the implant?

Check your knowledge

Are you confident discussing NEXPLANON® and other LARCs with women seeking contraception? Take our contraception questionnaire to check how much you know.

HCP: healthcare professional; LARC: long-acting reversible contraceptive

References

  1. NEXPLANON® Summary of Product Characteristics
  2. Depo-Provera Summary of Product Characteristics
  3. Faculty of Sexual & Reproductive Healthcare. Clinical guidance: progestogen-only injectable contraception. Available at: https://www.fsrh.org/standards-and-guidance/documents/cec-ceu-guidance-injectables-dec-2014/. Accessed July 2021
  4. Jeffreys L A, Clark A L. A successful approach to long-acting contraceptive implants in primary care. Contraception 2012;85(4):381-383
  5. Agrawal A, Robinson C. An assessment of the first 3 years' use of Implanon in Luton. J Fam Plann Reprod Health Care 2005;31(4):310-312
  6. Rai K, Gupta S, Cotter S. Experience with Implanon in a northeast London family planning clinic. Eur J Contracept Reprod Health Care 2004;9(1):39-46
  7. Lakha F, Glasier A F. Continuation rates of Implanon in the UK: data from an observational study in a clinical setting. Contraception 2006;74(4):287-289
  8. Faculty of Sexual & Reproductive Healthcare. Clinical guidance: progestogen-only implant. Available at: https://www.fsrh.org/standards-and-guidance/documents/cec-ceu-guidance-implants-feb-2014/. Accessed July 2021
  9. Faculty of Sexual & Reproductive Healthcare. Letter of competence subdermal contraceptive implants techniques insertion and removal (LoC SDI-IR). Available at: https://www.fsrh.org/education-and-training/letter-of-competence-subdermal-implants-loc-sdi/. Accessed July 2021
  10. Faculty of Sexual & Reproductive Healthcare. Letter of competence subdermal contraceptive implant techniques insertion only (LoC SDI-IO). Available at: https://www.fsrh.org/education-and-training/letter-of-competence-subdermal-implants-loc-sdi-insertion-only/. Accessed July 2021
  11. Mansour D, Mommers E et al. Clinician satisfaction and insertion characteristics of a new applicator to insert radiopaque Implanon: an open-label, noncontrolled, multicenter trial. Contraception 2010;82(3):243-249
  12. Levine J P, Sinofsky F E et al. Assessment of Implanon insertion and removal. Contraception 2008;78(5):409-417

GB-XPL-115062 | Date of preparation: July 2021